Showing 3781-3790 of 8598 results for "".
- Study: Lifileucel Shows Sustained Benefit in Advanced Melanoma Over 5 Yearshttps://practicaldermatology.com/news/lifileucel-shows-sustained-benefit-in-advanced-melanoma-over-5-years/2475031/Lifileucel showed sustained benefit and safety in a 5-year follow-up analysis of the phase II C-144-01 study in patients with advanced melanoma, according to a new study in the Journal of Clinical Oncology. Patien
- Study: Most Global Melanoma Cases Attributable to UV Exposurehttps://practicaldermatology.com/news/study-most-global-melanoma-cases-attributable-to-uv-exposure/2474874/A new global analysis of cutaneous melanoma (CM) shows ultraviolet radiation (UVR) as the primary driver behind the majority of CM cases worldwide in 2022. Researchers used updated incidence estimates from GLOBOCAN 2022 (exclud
- Assessment Tool Combination Reveals Higher AD Risk and Atopic March Progressionhttps://practicaldermatology.com/news/assessment-tool-combination-reveals-higher-ad-risk-and-atopic-march-progression/2474810/Children with Staphylococcus aureus (SA) detected by metagenomic sequencing, as well as culture-based methods, had worse atopic dermatitis (AD) outcomes, new study results suggest. Des
- Concerto Biosciences Completes Data Collection for Massive Skin Microbiome Interaction Projecthttps://practicaldermatology.com/news/concerto-biosciences-completes-data-collection-for-massive-skin-microbiome-interaction-project/2474768/Concerto Biosciences announced today that it has concluded the data acquisition phase of the Skin Universe Project (SUP), collecting over 33 million empirical data points in what it calls the largest known dataset of skin microbial interactions.
- Dermeleve to Modify Program for Sampleshttps://practicaldermatology.com/news/Dermeleve-Modify-Program-Samples/2474651/Dermeleve will transition away from its auto-ship model and self-serve request program for samples, but will still offer samples directly to patients and to clinicians who choose to hole wholesale inventory, the company said in an email to partners. “To ensure your patients can still ‘try
- New LED Mask Targets Acne, Redness, Aging in One Sessionhttps://practicaldermatology.com/news/new-led-mask-targets-acne-redness-aging-in-one-session/2474546/Smuuv Body has introduced the Lulu Pro LED Mask in what it says is the first at-home device to deliver five clinically validated wavelengths in a single treatment. A press release from the manufacturer reported that the mask, d
- Market for Atopic Dermatitis Treatments to Surge Past $22 Billionhttps://practicaldermatology.com/news/market-for-atopic-dermatitis-treatments-to-surge-past-22-billion/2474524/The global atopic dermatitis (AD) market is projected to more than double over the next decade, reaching $22.37 billion by 2034, new research from Polaris Market Research indicates. Driven by an annual growth rate of 8.5%, the
- Simvastatin Shows Promise as Adjunct Treatment for Vitiligo in Meta-Analysishttps://practicaldermatology.com/news/simvastatin-shows-promise-as-adjunct-treatment-for-vitiligo-in-meta-analysis/2474442/A new meta-analysis highlights the therapeutic potential of simvastatin for vitiligo, showing significant benefits in repigmentation and disease severity reduction. Vitiligo, an autoimmune disorder marked by melanocyte destruc
- Analysis: Drug Class Influences Clinical Management of Eruptive Keratoacanthoma/Squamous Cell Carcinomahttps://practicaldermatology.com/news/drug-class-influences-clinical-profile-and-management-of-eruptive-kascc/2474440/The clinical features and management of drug-induced eruptive keratoacanthoma (KA) and squamous cell carcinoma (SCC) differ significantly depending on the causative drug class, according to a new analysis of 172 reported cases.
- Triple-Combo Gel Reduces Acne Lesions, Scarring, and PIH Over 6 Months: Studyhttps://practicaldermatology.com/news/study-triple-combo-gel-reduces-acne-lesions-scarring-and-pih-over-6-months/2474438/Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) was associated with significant long-term efficacy and safety in the treatment of moderate acne and associated sequelae, results from a new 24-week open-label study indicate.